Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study84
Impact of SF3B1 mutation in myelofibrosis46
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma41
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia33
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant31
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review25
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia25
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma24
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis24
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents23
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia22
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination22
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma21
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study21
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia20
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis20
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes19
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma19
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management19
0.073174953460693